Literature DB >> 16779091

Use of the l1 norm for selection of sparse parameter sets that accurately predict drug response phenotype from viral genetic sequences.

Rabinowitz Matthew1, Milena Banjevic, A S Chan, Lance Myers, Roland Wolkowicz, Jessica Haberer, Joshua Singer.   

Abstract

We describe the use of the l1 norm for selection of a sparse set of model parameters that are used in the prediction of viral drug response, based on genetic sequence data of the Human Immunodeficiency Virus (HIV) reverse-transcriptase enzyme. We discuss the use of the l1 norm in the Least Absolute Selection and Shrinkage Operator (LASSO) regression model and the Support Vector Machine model. When tested by cross-validation with laboratory measurements, these models predict viral phenotype, or resistance, in response to Reverse-Transcriptase Inhibitors (RTIs) more accurately than other known models. The l1 norm is the most selective convex function, which sets a large proportion of the parameters to zero and also assures that a single optimal solution will be found, given a particular model formulation and training data set. A statistical model that reliably predicts viral drug response is an important tool in the selection of Anti-Retroviral Therapy. These techniques have general application to modeling phenotype from complex genetic data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16779091      PMCID: PMC1560612     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  24 in total

1.  Adherence--sticking to the evidence.

Authors:  L Sherr
Journal:  AIDS Care       Date:  2000-08

2.  Shrinkage estimators for covariance matrices.

Authors:  M J Daniels; R E Kass
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

3.  Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.

Authors:  Niko Beerenwinkel; Barbara Schmidt; Hauke Walter; Rolf Kaiser; Thomas Lengauer; Daniel Hoffmann; Klaus Korn; Joachim Selbig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

4.  Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.

Authors:  Andrea De Luca; Marilena Vendittelli; Francesco Baldini; Simona Di Giambenedetto; Maria Paola Trotta; Antonella Cingolani; Alessandra Bacarelli; Caterina Gori; Carlo Federico Perno; Andrea Antinori; Giovanni Ulivi
Journal:  Antivir Ther       Date:  2004-08

Review 5.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

6.  HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

Authors:  A R Zolopa; R W Shafer; A Warford; J G Montoya; P Hsu; D Katzenstein; T C Merigan; B Efron
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

7.  Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors.

Authors:  R W Shafer; P Hsu; A K Patick; C Craig; V Brendel
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 8.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

9.  Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.

Authors:  M N Rousseau; L Vergne; B Montes; M Peeters; J Reynes; E Delaporte; M Segondy
Journal:  J Acquir Immune Defic Syndr       Date:  2001-01-01       Impact factor: 3.731

10.  High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

Authors:  R W Shafer; K Hertogs; A R Zolopa; A Warford; S Bloor; B J Betts; T C Merigan; R Harrigan; B A Larder
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.